Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure

Journal of Cardiac Failure

Volumn 10, Issue 4, 2004, Pages 310-315

  Yoshizawa, Akihiro ^a   Yoshikawa, Tsutomu ^a   Nakamura, Iwao ^a   Satoh, Toru ^a   Moritani, Kazunori ^b   Suzuki, Masahiro ^b   Baba, Akiyasu ^b   Iwanaga, Shiro ^a   Mitamura, Hideo ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Keio University School of Medicine ^*

Author keywords

Carvedilol; Metoprolol; Neurohormone; Ventricular function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; METOPROLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDE, BRAIN; PROPANOLAMINES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 20844447682     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2003.10.011     Document Type: Article

References (22)

1. Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fikai D., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation. 96:1997;509-516
2. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal BNP (N-BNP) concentrations. Lancet. 355:2000;1126-1130
3. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J.S., Thompson S.G., Poole-Wilson P.A. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1347-1351
4. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167
5. Yoshikawa T., Baba A., Suzuki M., Yokozuka H., Okada Y., Nagami K., et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am J Cardiol. 85:2000;1495-1497
6. Yokota Y., Nomura H., Kawai H., Tsumura Y., Takeuchi Y., Kurozumi H., et al. Effects of long-term β-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J. 55:1991;343-355
7. Hirooka K., Yasumura Y., Ishida Y., Hanatani A., Nakatani S., Komamura K., et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J. 65:2001;931-936
8. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203
9. Yoshimura M., Yasue H., Okumura K., Ogawa H., Jougasaki M., Mukoyama M., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 87:1993;464-469
10. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 88:1993;82-91
11. Omland T., Aakvaag A., Bonarjee V.V.S., Caidahl K., Lie R.T., Nilsen D.W.T., et al. Plasma brain natrivretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 93:1996;1963-1969
12. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 102:2000;865-870
13. The Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 99:1999;786-792
14. Hara Y., Hamada M., Shigematsu Y., Suzuki M., Kodama K., Kuwahara T., et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J. 64:2000;365-369
15. Fujimura M., Yasumura Y., Ishida Y., Nakatani S., Komamura K., Yamagishi M., et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 6:2000;3-10
16. Kawai K., Hata K., Takaoka H., Kawai H., Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 141:2001;925-932
17. Sanderson J.E., Chan W.W.M., Hung Y.T., Chan S.K.W., Shum I.O.L., Raymond K., et al. Effect of low dose β blockers on atrial and ventricular (B type) natriuretic factor in heart failure: double blind, randomised comparison of metoprolol and a third generation vasodilating β blocker. Br Heart J. 74:1995;502-507
18. The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation. 101:2000;378-384
19. Stanek B., Frey B., Hülsmann M., Berger R., Strametz-Juranek J., Sturm B., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 38:2001;436-442
20. Yoshimoto T., Naruse M., Tanabe A., Naruse K., Seki T., Imaki T., et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 139:1998;81-88
21. Luchner A., Burnett J.C. Jr., Jougasaki M., Hense H., Riegger G.A.J., Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 32:1998;1839-1844
22. Ohtsuka T., Hamada M., Saeki H., Ogimoto A., Hiasa G., Hara Y., et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 89:2002;996-999